Completed PHASE3 NCT00829374

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil

Sponsor: Medivation, Inc.

Conditions Alzheimer's Disease

Interventions Dimebon Placebo comparator

Updated 8 times since 2017 Last updated: Sep 24, 2016 Started: Mar 31, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This PHASE3 trial investigates Alzheimer's Disease and is currently completed. Medivation, Inc. leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medivation, Inc.
Pfizer

Data source: Medivation, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Albany, United States , Ann Arbor, United States , Antwerp, Belgium , Atlanta, United States , Auckland, New Zealand , Austin, United States , Bath, United Kingdom , Beachwood, United States , Berlin, Germany and 91 more locations